Medtronic plc
NYSE:MDTMedical - Devices
+$0.75 today
- Market cap
- $128.84B
- Beta
- 0.60
- P/E (TTM)
- 21.1
- EPS (TTM)
- $3.74
- Dividend yield
- 3.60%
Volume 6.47M
Average 11.36M
MDT EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Medtronic plcNYSE: MDT
EBITDA · Q1 FY2027 · quarter ended Jul 2026
EBITDA growth accelerates
Q1 FY2027 EBITDA of $2.68B rose 20.6% year over year, ahead of the +9.8% change in trailing-twelve-month EBITDA. Sequentially, it fell 1.6% from the prior quarter. Over 3 fiscal years it compounded at +4.1% a year.
Context
- EBITDA amounted to 27.0% of revenue in FY2026, down 0.5 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 21 analysts of $13.13B (+33.9%) for the fiscal year ending Apr 2027, a step up from the +6.4% reported in FY2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJul 2026
- $2.68B-1.6% QoQ
- Last fiscal yearApr 2026
- $9.81B+6.4% YoY
- LTMJul 2026
- $10.27B+9.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +20.6% | +20.9% | +0.3 pp |
| 1 year | +6.4% | +33.9% | +27.5 pp |
| 3-year CAGR | +4.1% | +13.1% | +9.0 pp |
| 5-year CAGR | +10.6% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2026
- 9.81B USD
- Year-over-year change
- +6.4%
- 4-year CAGR
- +2.8%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2026 | 2026-04-24 | 9.81B | +6.4% |
| FY2025 | 2025-04-25 | 9.22B | +12.4% |
| FY2024 | 2024-04-26 | 8.2B | -5.7% |
| FY2023 | 2023-04-28 | 8.7B | -0.9% |
| FY2022 | 2022-04-29 | 8.78B | — |
EBITDA vs competitors
How MDT compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +9.8% is the 6th highest of 9, against a peer median of +19.0%.
- EBITDA amounts to 27.3% of revenue for MDT, versus a peer median of 25.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $10.27B USD | +9.8% | +4.1% | 27.3% | |
| LTM Jun 2026 | $6.69B USD | +40.7% | +16.3% | 25.9% | |
| LTM Jun 2026 | $5.8B USD | +23.2% | +23.0% | 27.6% | |
| LTM Jun 2026 | €3.05B EUR | +62.1% | +184.2% | 17.3% | |
| LTM Jun 2026 | $2.34B USD | +2.7% | +14.1% | 27.5% | |
| LTM Jun 2026 | $1.58B USD | -11.2% | -9.6% | 24.3% | |
| LTM Jun 2026 | $222.27M USD | +14.8% | +95.5% | 14.8% | |
| LTM Sep 2026 | $211.36M USD | +363.4% | — | 14.0% | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | -$92.94M USD | -14.3% | — | 5021.0% |
| Peer median (excluding MDT) | — | +19.0% | +19.6% | 25.1% | |
Competitors are the stored peer set for MDT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Apr 2022 | FY2023 Apr 2023 | FY2024 Apr 2024 | FY2025 Apr 2025 | FY2026 Apr 2026 |
|---|---|---|---|---|---|
| Revenue | 31.69B | 31.23B | 32.36B | 33.54B | 36.36B |
| Cost of Revenue | 10.15B | 10.72B | 11.22B | 11.63B | 12.72B |
| Gross Profit | 21.54B | 20.51B | 21.15B | 21.91B | 23.64B |
| Gross Margin | 68.0% | 65.7% | 65.3% | 65.3% | 65.0% |
| Research & Development | 2.75B | 2.7B | 2.74B | 2.73B | 2.87B |
| Selling, General & Admin | 10.29B | 10.42B | 10.74B | 10.85B | 11.78B |
| Operating Expenses | 15.79B | 15.02B | 16B | 15.95B | 17.18B |
| Depreciation & Amortization | 2.71B | 2.7B | 2.65B | 2.86B | 2.96B |
| EBITDA | 8.78B | 8.7B | 8.2B | 9.22B | 9.81B |
| EBITDA Margin | 27.7% | 27.9% | 25.3% | 27.5% | 27.0% |
| Operating Income | 5.75B | 5.49B | 5.14B | 5.96B | 6.47B |
| Operating Margin | 18.2% | 17.6% | 15.9% | 17.8% | 17.8% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 553M | 636M | 719M | 729M | 715M |
| Other Income / Expenses | (235M) | (121M) | (307M) | (327M) | (331M) |
| Income Before Tax | 5.52B | 5.36B | 4.84B | 5.63B | 6.14B |
| Pre-Tax Margin | 17.4% | 17.2% | 14.9% | 16.8% | 16.9% |
| Income Tax Expense | 456M | 1.58B | 1.13B | 936M | 1.3B |
| Net Income | 5.04B | 3.76B | 3.68B | 4.66B | 4.8B |
| Net Margin | 15.9% | 12.0% | 11.4% | 13.9% | 13.2% |
| EPS (Basic) | 3.75 | 2.83 | 2.77 | 3.63 | 3.75 |
| EPS (Diluted) | 3.73 | 2.82 | 2.76 | 3.61 | 3.73 |
| Weighted Avg Shares | 1.34B | 1.33B | 1.33B | 1.29B | 1.28B |
| Weighted Avg Shares (Diluted) | 1.35B | 1.33B | 1.33B | 1.29B | 1.29B |
Medtronic plc
NYSE:MDT
Intrinsic Alpha fair value
Locked
Current Price
$100.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.